AI Article Synopsis
- A preclinical trial found that 20% of gastric cancer patient-derived xenografts responded positively to the drug cetuximab.
- High levels of EGFR mRNA expression and a strong immunohistochemistry score (3+) were linked to reduced tumor growth.
- Among the responders, 50% showed EGFR amplification, indicating that certain gastric cancer subtypes with EGFR overexpression may benefit from cetuximab treatment.
Article Abstract
A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801116 | PMC |
| http://dx.doi.org/10.1038/srep02992 | DOI Listing |
Publication Analysis
Top Keywords
egfr amplification
12
amplification overexpression
8
subset gastric
4
gastric cancers
4
egfr
4
cancers egfr
4
overexpression respond
4
respond cetuximab
4
cetuximab therapy
4
therapy preclinical
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!